Search for: "Genentech Inc." Results 181 - 200 of 469
Sorted by Relevance | Sort by Date
RSS Subscribe: 20 results | 100 results
27 Feb 2014, 9:38 am by Dennis Crouch
See In re Genentech, Inc., 566 F.3d 1338, 1345 (Fed. [read post]
19 May 2011, 9:34 pm by Lawrence B. Ebert
Genentech, Inc., the Supreme Court rejected our prior, more stringent standard for declaratory judgment stand- ing insofar as it required a “reasonable apprehension of imminent suit. [read post]
15 Apr 2010, 5:46 am by Lawrence B. Ebert
The rub:Although the PTO emphasizes that it was required to give all “claims their broadest reasonable construction” particularly with respect to claim 4’s use of the open- ended term “comprising,” see Genentech, Inc. v. [read post]
15 Jul 2011, 7:41 am by Cara Disisto
/Genentech Inc. (153), Advanced Cardiovascular Systems (Abbott Vascular) (142), and Agilent Technologies (129). [read post]
29 Aug 2013, 9:49 am by Dennis Crouch
Genentech, Inc., 549 U.S. 118, 127 (2007), the appellate court here retreats at least from more liberal interpretations of that decision. [read post]
21 Mar 2018, 7:43 pm by Scott McKeown
Genentech, Inc., Case IPR2017-00739 (PTAB July 27, 2017) (Paper 16)Hospira, Inc. v. [read post]
13 Jul 2007, 3:18 pm
Genentech, Inc. -- standing to sue for patent declaratory judgment Microsoft Corp. v. [read post]
25 May 2017, 8:40 am by Tom Lamb
We will continue to follow this possible safety issue for Ocrevus, a new multiple sclerosis (MS) from Genentech and Roche. [read post]
21 Jul 2008, 10:26 am
(July 8, 2008), the Tenth Circuit applied MedImmune, Inc. v. [read post]
21 Nov 2012, 5:00 am by Bexis
Pfizer Inc., 58 A.D.3d 138, 141 (N.Y. [read post]
24 Jan 2013, 6:51 am by David Jensen
Anne Marie Duliege , vice president of Affymax Michael Freidman, CEO City of Hope Michael Goldberg, executive chairman of Nodality, Inc., and DNAnexus, appointed as executive officer of a commercial life science entity Sam Hawgood, dean of the UC San Francisco medical school Steve Juelsgaard, former executive vice president of Genentech, appointed as executive officer of a commercial life science entity Sherry Lansing, chairwoman of the UC board of regents, appointed… [read post]
28 May 2015, 4:35 pm by David Jensen
Steve Juelsgaard, former executive vice president of Genentech, asked about the company’s “plan B. [read post]
10 Apr 2016, 1:47 am by Mark Summerfield
  However, many cases fall somewhere between these two extremes, with an opposition being only partly successful, and/or the Hearing Officer finding that successful grounds of opposition might nonetheless be overcome by some form of amendment to the patent specification and claims.An example of this last type of outcome is the subject of a recent decision of the Federal Court of Australia in Merck Sharpe & Dohme (Australia) Pty Ltd v Genentech Inc [2016] FCA 324, which… [read post]
28 Jun 2009, 2:11 pm by Tom Casagrande
Tex. as good as any other district for that purpose.In In re Genentech Inc. and Biogen, Inc., No. [read post]